Antibiotic Stewardship Monitoring and Timely Start Deficiencies
Summary
The facility failed to implement its antibiotic stewardship program for two residents receiving antibiotics. For one resident admitted with ulcerative colitis, elevated WBC count, and cholangitis, the record showed an order for ertapenem sodium 1 gram IV every 24 hours for elevated WBCs for 7 days, to begin once blood cultures were drawn. The resident’s care plan addressed risk for infection and reducing MDRO transmission, but it did not include any intervention to monitor for adverse effects from ertapenem. During interview, the RN stated there was no order or care plan intervention for monitoring adverse effects, and the DON stated the antibiotic should have been monitored for adverse side effects and documented in progress notes. The facility’s antibiotic stewardship policies required documentation of antibiotic use, adverse events, and monitoring of outcomes, but those elements were not reflected in the resident’s record. For the second resident, admitted with UTI, sepsis, and generalized muscle weakness, the physician ordered linezolid 600 mg by mouth every 12 hours for 7 days, with a start date of 3/11/2026 and end date of 3/18/2026. The care plan for UTI included administering antibiotic therapy as ordered and monitoring for adverse reactions. The MAR showed the first dose of linezolid was administered on 3/11/2026 at 9 a.m., and the IP stated the facility’s standard practice was to start new antibiotic orders within 4 hours of receiving the order. The IP and DON both stated the first dose should have been started within 4 hours, but the record did not show that the medication was started timely. The progress notes for the resident receiving linezolid did not specify monitoring for adverse side effects. During interview, the IP stated residents on antibiotics are supposed to be monitored every shift and that documentation should include the specific adverse effects being monitored. The IP also stated the notes did not specify adverse side effects to watch for, and the DON stated monitoring should be specific and documented so the physician can be notified immediately if needed. The manufacturer information reviewed by the facility listed common adverse reactions to linezolid as diarrhea, vomiting, headache, and nausea. The facility policies also stated that residents receiving medications with potential adverse consequences should be monitored and that adverse events related to antibiotic use should be tracked and reported.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.